

Financial news for ADMS dated on 2020-06-08: 33 Stocks Moving in Monday's Pre-Market Session

Financial news for ADMS dated on 2020-06-08: 102 Biggest Movers From Friday

Financial news for ADMS dated on 2020-06-05: 75 Stocks Moving In Friday's Mid-Day Session

Financial news for ADMS dated on 2020-06-05: The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets \$400M Bid

Financial news for ADMS dated on 2020-06-05: 40 Stocks Moving in Friday's Pre-Market Session

Financial news for ADMS dated on 2020-06-04: Adamas Announces FDA Filing Acceptance Of sNDA To Modify The Indication Statement For GOCOVRI To Include Treatment For Parkinson's Disease Patients Receiving Levodopa And Experiencing OFF Episodes

Financial news for ADMS dated on 2020-05-13: Adamas Announces Issuance Of New US Patent For Gocovri In Parkinson's Disease, Expands Coverage With Reduction Of 'Off' Time And Increased 'Good ON' Time

Financial news for ADMS dated on 2020-05-11: 96 Biggest Movers From Friday

Financial news for ADMS dated on 2020-05-08: 70 Stocks Moving In Friday's Mid-Day Session

Financial news for ADMS dated on 2020-05-07: Adamas Pharmaceuticals Q1 EPS \$(0.590) Beats \$(0.790) Estimate, Sales \$14.481M Miss \$15.360M Estimate

Financial news for ADMS dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500

Financial news for ADMS dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for ADMS dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for ADMS dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for ADMS dated on 2020-03-11: Stocks That Hit 52-Week Lows On Wednesday

Financial news for ADMS dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for ADMS dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for ADMS dated on 2020-02-25: Adamas Pharmaceuticals Q4 EPS \$(0.83) Beats \$(0.85) Estimate, Sales \$16.348M Beat \$15.81M Estimate

Financial news for ADMS dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for ADMS dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for ADMS dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for ADMS dated on 2020-02-11: Adamas Pharma Highlights Publication Of 2-Year Phase 3 Open-Label EASE LID 2 Trial Of GOCOVRI For Dyskinesia In Patients With Parkinson's Disease

Financial news for ADMS dated on 2020-01-27: 70 Biggest Movers From Friday

Financial news for ADMS dated on 2020-01-09: 54 Biggest Movers From Yesterday

Financial news for ADMS dated on 2020-01-08: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ADMS dated on 2020-01-02: Adamas Announces Settlement of Patent Litigation with Sandoz Inc.; Co. Grants Sandoz License For Its Generic Version Of GOCOVRI

Financial news for ADMS dated on 2019-12-19: 36 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for ADMS dated on 2019-12-19: 64 Biggest Movers From Yesterday

Financial news for ADMS dated on 2019-12-18: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ADMS dated on 2019-12-18: 68 Biggest Movers From Yesterday

Financial news for ADMS dated on 2019-12-17: Mid-Afternoon Market Update: Crude Oil Rises Over 1%; ImmunoGen Shares Spike Higher

Financial news for ADMS dated on 2019-12-17: UPDATE: Cantor Fitzgerald Reiterates Neutral On Adamas Pharmaceuticals, Lowers Target To \$7 Notes 'INROADS P3 Doesn't Lead to Gocovri Label-Expansion Inroads, Yet'; Firm Sees Possible Clarity 'by mid-20'

Financial news for ADMS dated on 2019-12-17: Cantor Fitzgerald Reiterates Neutral on Adamas Pharmaceuticals, Lowers Price Target to \$7

Financial news for ADMS dated on 2019-12-17: Mid-Day Market Update: Tallgrass Energy Jumps Following Acquisition News; Proteostasis Therapeutics Shares Plummet

Financial news for ADMS dated on 2019-12-17: 42 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ADMS dated on 2019-12-17: Adamas Pharmaceuticals shares are trading lower after the company reported its Phase 3 trial of ADS-5102 for multiple sclerosis patients with walking impairments did not show significant effect on secondary walking measures despite achieving the primary endpoint.

Financial news for ADMS dated on 2019-12-17: Hearing Evercore ISI Reiterating A \$45 Price Target On Adamas Pharma, Following News Tues. Phase 3 Trial Of ADS-5102 Did Not Meet Primary Endpoint, Firm Highlights Belief Issue With Trial Could Be 'the final of many mistakes from prior mgmt....'

Financial news for ADMS dated on 2019-12-17: Mid-Morning Market Update: Markets Edge Higher; Jabil Beats Q1 Expectations

Financial news for ADMS dated on 2019-12-17: Adamas Pharmaceuticals Shares Resume Trade, Now Halted Again On Circuit Breaker

Financial news for ADMS dated on 2019-12-17: Adamas Pharmaceuticals Shares To Resume Trade At 9:50 a.m. EDT

Financial news for ADMS dated on 2019-12-17: Adamas Pharmaceuticals To Assess Potential For ADS-5102 Before Deciding Continued Investment In Program

Financial news for ADMS dated on 2019-12-17: Adamas Pharmaceuticals Announces INROADS Phase 3 Trial Of ADS-5102 For Multiple Sclerosis Patients With Walking Impairment Achieved Primary Endpoint But Did Not Demonstrate Significant Effect On Secondary Walking Measures

Financial news for ADMS dated on 2019-12-17: Adamas Pharmaceuticals Shares Halted News Pending

Financial news for ADMS dated on 2019-12-04: 26 Stocks Moving in Wednesday's Pre-Market Session

Financial news for ADMS dated on 2019-12-04: The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

Financial news for ADMS dated on 2019-12-03: Adamas Pharmaceuticals Inc Files For Common Stock Offering Of Up To \$50M

Financial news for ADMS dated on 2019-11-11: 80 Biggest Movers From Friday

Financial news for ADMS dated on 2019-11-08: The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

Financial news for ADMS dated on 2019-11-07: Adamas Pharmaceuticals Q3 EPS \$(0.99) Misses \$(0.89) Estimate, Sales \$13.933M Miss \$14.07M Estimate

Financial news for ADMS dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for ADMS dated on 2019-10-14: 58 Biggest Movers From Friday

Financial news for ADMS dated on 2019-10-11: The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout

Financial news for ADMS dated on 2019-10-10: Stocks That Hit 52-Week Lows On Thursday

Financial news for ADMS dated on 2019-10-10: The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO

Financial news for ADMS dated on 2019-10-09: Stocks That Hit 52-Week Lows On Wednesday

Financial news for ADMS dated on 2019-10-09: The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug

Financial news for ADMS dated on 2019-10-09: 42 Biggest Movers From Yesterday

Financial news for ADMS dated on 2019-10-07: 45 Biggest Movers From Friday

Financial news for ADMS dated on 2019-10-04: The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering

Financial news for ADMS dated on 2019-10-03: Stocks That Hit 52-Week Lows On Thursday

Financial news for ADMS dated on 2019-10-03: The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo

Financial news for ADMS dated on 2019-10-02: The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data

Financial news for ADMS dated on 2019-10-02: 52 Biggest Movers From Yesterday

Financial news for ADMS dated on 2019-10-01: Stocks That Hit 52-Week Lows On Tuesday

Financial news for ADMS dated on 2019-10-01: 58 Biggest Movers From Yesterday

Financial news for ADMS dated on 2019-09-30: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for ADMS dated on 2019-09-30: Mid-Day Market Update: Thor Industries Surges On Earnings Beat; Benitec Biopharma Shares Slide

Financial news for ADMS dated on 2019-09-30: Benzinga's Top Upgrades, Downgrades For September 30, 2019

Financial news for ADMS dated on 2019-09-30: Bank of America Downgrades Adamas Pharmaceuticals to Underperform

Financial news for ADMS dated on 2019-09-20: Adamas Announces New Safety And Efficacy Data For GOCOVRI In Parkinson's Disease Patients With Dyskinesia At Movement Disorder Society 2019 International Congress

Financial news for ADMS dated on 2019-09-13: Adamas Pharma Names Neil McFarlane CEO; David Mahoney Named Chair

Financial news for ADMS dated on 2019-09-09: Benzinga's Top Upgrades, Downgrades For September 9, 2019

Financial news for ADMS dated on 2019-09-09: Cantor Fitzgerald Initiates Coverage On Adamas Pharmaceuticals with Neutral Rating, Announces \$8 Price Target

Financial news for ADMS dated on 2019-08-09: The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2

Financial news for ADMS dated on 2019-08-08: 50 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for ADMS dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for ADMS dated on 2019-08-03: The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Financial news for ADMS dated on 2019-07-25: 35 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for ADMS dated on 2019-07-02: 32 Stocks Moving In Tuesday's Pre-Market

Session

Financial news for ADMS dated on 2019-06-19: Adamas Pharma 13G Filing From Stonepine Capital Shows Raised Stake From ~984K Shares To ~1.52M Shares, Or 5.5%

Financial news for ADMS dated on 2019-06-19: The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut

Financial news for ADMS dated on 2019-06-12: The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana

Financial news for ADMS dated on 2019-05-29: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ADMS dated on 2019-05-16: 50 Stocks Moving In Thursday's Mid-Day Session

Financial news for ADMS dated on 2019-05-10: The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales

Financial news for ADMS dated on 2019-05-09: Adamas Pharmaceuticals Q1 EPS \$(1.08) Beats \$(1.15) Estimate, Sales \$11.665M Miss \$12.31M Estimate

Financial news for ADMS dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for ADMS dated on 2019-05-07: Adamas Announces Data Presentations at #AAN2019

Financial news for ADMS dated on 2019-04-11: The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug

Financial news for ADMS dated on 2019-04-10: The Daily Biotech Pulse: Amgen's Bone-Building Osteoporosis Drug Clears FDA Muster, PhaseBio Offering

Financial news for ADMS dated on 2019-04-04: The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Drove, Silk Road, NGM Biopharma To Debut

Financial news for ADMS dated on 2019-03-28: The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO

Financial news for ADMS dated on 2019-03-26: The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

Financial news for ADMS dated on 2019-03-06: 71 Biggest Movers From Yesterday

Financial news for ADMS dated on 2019-03-05: Mid-Afternoon Market Update: YY Rises After Q4 Results; Atlas Financial Shares Fall

Financial news for ADMS dated on 2019-03-05: 56 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ADMS dated on 2019-03-05: Mid-Day Market Update: Ctrip.Com Climbs Following Upbeat Q4 Results; Barnes & Noble Education Shares Slide

Financial news for ADMS dated on 2019-03-05: Mid-Morning Market Update: Markets Open Lower; Target Tops Q4 Expectations

Financial news for ADMS dated on 2019-03-05: 10 Biggest Price Target Changes For Tuesday

Financial news for ADMS dated on 2019-03-05: Needham Downgrades Adamas Pharmaceuticals to Hold

Financial news for ADMS dated on 2019-03-05: Benzinga's Top Upgrades, Downgrades For March 5, 2019

Financial news for ADMS dated on 2019-03-05: 36 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ADMS dated on 2019-03-05: Adamas Pharmaceuticals shares are trading lower; the company reportedly suspended 2019 revenue guidance amid expected near-term unevenness in prescription growth and challenges related to plan switches. Multiple analysts downgraded the stock

Financial news for ADMS dated on 2019-03-05: The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings

Financial news for ADMS dated on 2019-03-05: Cowen & Co. Downgrades Adamas Pharmaceuticals to Market Perform, Lowers Price Target to \$15

Financial news for ADMS dated on 2019-03-05: Mizuho Downgrades Adamas Pharmaceuticals to Underperform, Lowers Price Target to \$5

Financial news for ADMS dated on 2019-03-04: Adamas Pharmaceuticals, Inc. - Common Stock Q4 EPS \$(1.06) Beats \$(1.34) Estimate, Sales \$13.315M Beat \$13.26M Estimate

Financial news for ADMS dated on 2019-03-04: Earnings Scheduled For March 4, 2019

Financial news for ADMS dated on 2019-03-03: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for ADMS dated on 2019-01-06: Adamas Expects Net Sales of GOCOVRI to be ~\$13.3M for Q4 Ended December 31, 2018; Preliminary FY Unaudited Net Sales of GOCOVRI Expected to be ~\$34M

Financial news for ADMS dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for ADMS dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for ADMS dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for ADMS dated on 2018-12-18: Adamas Announces Issuance Of New U.S. Patent Covering GOCOVRI

Financial news for ADMS dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for ADMS dated on 2018-11-21: Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018

Financial news for ADMS dated on 2018-11-21: The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novellion CEO

Financial news for ADMS dated on 2018-11-20: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018

Financial news for ADMS dated on 2018-11-20: The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings

Financial news for ADMS dated on 2018-11-19: Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018

Financial news for ADMS dated on 2018-11-13: Leerink Swann Initiates Coverage On Adamas Pharmaceuticals with Outperform Rating, Announces \$20 Price Target

Financial news for ADMS dated on 2018-11-06: The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

Financial news for ADMS dated on 2018-11-05: 10 Biggest Price Target Changes For Monday

Financial news for ADMS dated on 2018-11-05: Benzinga's Top Upgrades, Downgrades For November 5, 2018

Financial news for ADMS dated on 2018-11-05: Mizuho Downgrades Adamas Pharmaceuticals to Neutral, Lowers Price Target to \$18

Financial news for ADMS dated on 2018-11-05: 74 Biggest Movers From Friday

Financial news for ADMS dated on 2018-11-02: 64 Stocks Moving In Friday's Mid-Day Session

Financial news for ADMS dated on 2018-11-01: Adamas Pharmaceuticals Q3 EPS \$(1.22) Beats \$(1.34) Estimate, Sales \$10.6M Beat \$10.17M Estimate

Financial news for ADMS dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for ADMS dated on 2018-10-31: The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

Financial news for ADMS dated on 2018-10-08: Stocks Which Set New 52-Week Low Friday, October 5th

Financial news for ADMS dated on 2018-10-08: Adamas Pharma Reports its Phase 3 Study of GOCOVRI was 'Generally Well Tolerated'

Financial news for ADMS dated on 2018-10-08: 46 Biggest Movers From Friday

Financial news for ADMS dated on 2018-10-05: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for ADMS dated on 2018-10-05: Benzinga's Top Upgrades, Downgrades For October 5, 2018

Financial news for ADMS dated on 2018-10-05: Bank of America Downgrades Adamas Pharmaceuticals to Neutral, Lowers Price Target to \$25

Financial news for ADMS dated on 2018-10-04: Adamas Announces Publication Of Data Demonstrating Dyskinesia's Impact On Activities Of Daily Living In People With Parkinson's Disease

Financial news for ADMS dated on 2018-09-24: UPDATE: Adamas Counterclaims Assert Osmotica Has Infringed Nine Adamas Patents

Financial news for ADMS dated on 2018-09-24: Adamas Pharmaceuticals In 8-k Announces Co Has Filed First Amended Answer Including Infringement Counterclaims Against Osmotica Pharmaceuticals And Vertical Pharmaceuticals In Its Ongoing Litigation Concerning Osmolex

Financial news for ADMS dated on 2018-08-06: Adamas Pharmaceuticals Says FAERS Data Is Consistent With Prescribing Info, As Noted By FDA, Reports Not Necessarily Casually Related

Financial news for ADMS dated on 2018-08-06: Adamas Pharma Shares Dip 2.7% Lower As Traders Circulate Word An FDA Site Is Listing 3 Deaths Possibly Related To The Company's Gocovri

Financial news for ADMS dated on 2018-08-03: 56 Stocks Moving In Friday's Mid-Day Session

Financial news for ADMS dated on 2018-08-03: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for ADMS dated on 2018-08-03: The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

Financial news for ADMS dated on 2018-08-02: Adamas Pharmaceuticals shares are trading up 14.5 percent after the company beat Q2 earnings estimates

Financial news for ADMS dated on 2018-08-02: 8 Stocks Moving In Thursday's After-Hours Session

Financial news for ADMS dated on 2018-08-02: Adamas Pharmaceuticals Q2 EPS \$(1.26) Beats \$(1.41) Estimate, Sales \$7.565M Beat \$4.86M Estimate

Financial news for ADMS dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for ADMS dated on 2018-07-16: H.C. Wainwright Initiates Coverage On Adamas Pharmaceuticals with Buy Rating, Announces \$45 Price Target

Financial news for ADMS dated on 2018-05-24: Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI in Clinical Pharmacokinetics

Financial news for ADMS dated on 2018-05-04: Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down

Financial news for ADMS dated on 2018-05-03: Adamas Pharmaceuticals Q1 EPS \$(1.35) Beats \$(1.37) Estimate, Sales \$2.6M Beat \$1.6M Estimate

Financial news for ADMS dated on 2018-05-03: Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss

Financial news for ADMS dated on 2018-04-19: Adamas Announces Final Results From Two-Year Phase 3 Open-Label Study Of GOCOVRI In Parkinson's Disease Patients With Dyskinesia

Financial news for ADMS dated on 2018-03-27: Gocovri Stabilizes Adamas Stock, Secures Another Buy Rating

Financial news for ADMS dated on 2018-03-27: Benzinga's Top Upgrades, Downgrades For March 27, 2018

Financial news for ADMS dated on 2018-03-27: Bank of America Initiates Coverage On Adamas Pharmaceuticals with Buy Rating, Announces \$39.00 Price Target

Financial news for ADMS dated on 2018-03-27: 24 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ADMS dated on 2018-03-12: Shares of Adamas Pharmaceuticals Up 8.3% Premarket On Earlier 8-K Filing That Said Co. Received GOCOVRI From ~390 Distinct Prescribers, Filled GOCOVRI Prescriptions For The Period Of Jan. 1st, 2018 To Feb. 28th 2018 Were 742

Financial news for ADMS dated on 2018-02-26: 46 Biggest Movers From Yesterday

Financial news for ADMS dated on 2018-02-23: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for ADMS dated on 2018-02-23: Adam Feuerstein Tweets: Evercore ISI's Josh Schimmer is in full panic mode on \$ADMS. His note this morning could have been ripped directly from a message board post. He's making an uncertain situation worse. Rethink, Josh.

Financial news for ADMS dated on 2018-02-22: Adamas Pharma Reports Q4 EPS \$(1.27) vs. \$(1.26) Est., Sales \$568K vs. \$840K Est.

Financial news for ADMS dated on 2018-02-22: Adamas Pharmaceuticals Earnings Preview

Financial news for ADMS dated on 2018-02-21: 34 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ADMS dated on 2018-02-21: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ADMS dated on 2018-02-21: 40 Biggest Movers From Yesterday

Financial news for ADMS dated on 2018-02-20: Adamas Pharma Shares Down 18.7% Following Earlier Announcement of Action Filed In Delaware Court By Osmotica and Vertical Pharmaceuticals Companies Regarding Its OSMOLEX ER Tablets; Co. Noted Complaint Does Not Allege Patent Infringement

Financial news for ADMS dated on 2018-02-20: 32 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ADMS dated on 2018-02-20: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ADMS dated on 2018-02-20: Adamas Announces Declaratory Judgment Action Filed by Osmotica Related to Approved OSMOLEX ER

Financial news for ADMS dated on 2018-02-08: The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease

Financial news for ADMS dated on 2018-02-01: Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal

Financial news for ADMS dated on 2018-01-23: Adamas Pharma Prices 3M Share Offering @\$41.50/Share

Financial news for ADMS dated on 2018-01-23: 10 Stocks To Watch For January 23, 2018

Financial news for ADMS dated on 2018-01-22: 11 Stocks Moving In Monday's After-Hours Session

Financial news for ADMS dated on 2018-01-22: Adamas Announces \$85M Common Stock Offering

Financial news for ADMS dated on 2018-01-08: Adamas Pharma Announces U.S. Launch Of GOCOVRI

Financial news for ADMS dated on 2017-12-19: 7 Stocks Ready To Climb Another 30% in 2018

Financial news for ADMS dated on 2017-12-01: Adamas Pharma Option Alert: Jan 19 \$30 Calls Sweep (2) at the Bid: 1000 @ \$7.0 vs 162 OI; Ref=\$36.1

Financial news for ADMS dated on 2017-11-29: Adamas Pharmaceutical Shares Up 4.64%;

Hearing Northland Capital Earlier Initiated Coverage With Outperform Rating And \$70 Price Target, Unconfirmed

Financial news for ADMS dated on 2017-11-08: Adamas Shares Volatile Off The Open As Traders Circulate Unconfirmed Chatter Of M&A Interest

Financial news for ADMS dated on 2017-11-02: Adamas Pharmaceuticals Reports Q3 EPS \$(1.04) vs \$(0.98) Est., Sales \$1K vs \$30K Est.

Financial news for ADMS dated on 2017-11-01: Adamas Pharma's Gocovri Will Achieve 'Blockbuster' Status, Says Kerrisdale

Financial news for ADMS dated on 2017-11-01: Kerrisdale Capital Says Adamas Pharmaceutical Lead Drug Gocovri Will Achieve 'Blockbuster' Status, Says Earlier-Stage Pipeline Assets Alone Are Worth Billions

Financial news for ADMS dated on 2017-11-01: Adamas Pharma 13G Filing From Kerrisdale Shows 6.5% Stake

Financial news for ADMS dated on 2017-10-31: 40 Biggest Movers From Yesterday

Financial news for ADMS dated on 2017-10-30: Adamas Pharmaceuticals Sharply Higher Off New Outperform Rating

Financial news for ADMS dated on 2017-10-30: 35 Stocks Moving In Monday's Mid-Day Session

Financial news for ADMS dated on 2017-10-30: Benzinga's Top Upgrades, Downgrades For October 30, 2017

Financial news for ADMS dated on 2017-10-30: Evercore ISI Group Initiates Coverage On Adamas Pharmaceuticals with Outperform Rating, Announces \$85.00 Price Target

Financial news for ADMS dated on 2017-10-30: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for ADMS dated on 2017-10-04: Benzinga's Option Alert Recap From October 4

Financial news for ADMS dated on 2017-10-04: Adamas Option Alert: Dec 15 \$22.5 Calls Sweep (9) at the Ask: 614 @ \$2.65 vs 459 OI; Ref=\$22.1

Financial news for ADMS dated on 2017-09-19: 10 Biggest Mid-Day Gainers For Tuesday

Financial news for ADMS dated on 2017-09-19: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ADMS dated on 2017-09-18: Adamas Pharmaceuticals, Hi-Crush Partners Holding Analyst/Investor Days Today

Financial news for ADMS dated on 2017-09-07: Adamas Reports Topline Phase 1b Data of ADS-4101, Was Safe And Well-Tolerated Across All 3 Doses

Financial news for ADMS dated on 2017-09-01: Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts

Financial news for ADMS dated on 2017-08-25: Mid-Afternoon Market Update: GameStop Drops After Mixed Q2 Report; Pure Storage Shares Surge

Financial news for ADMS dated on 2017-08-25: 18 Biggest Mid-Day Gainers For Friday

Financial news for ADMS dated on 2017-08-25: Adamas Up 40% After FDA Approval Of Gocovri

Financial news for ADMS dated on 2017-08-25: Adamas Pharma's Gocovri Approved, A Welcome Addition To Parkinson's Treatments

Financial news for ADMS dated on 2017-08-25: Mid-Day Market Update: Adamas Pharma Climbs Following FDA Approval of GOCOVRI; Aceto Shares Plummet

Financial news for ADMS dated on 2017-08-25: Mid-Morning Market Update: Markets Open Higher; Big Lots Profit Tops Estimates

Financial news for ADMS dated on 2017-08-25: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for ADMS dated on 2017-08-25: Adamas Pharma +49% Premarket @\$21.20 Following Announcement of FDA Approval of GOCOVRI

Financial news for ADMS dated on 2017-08-24: Adamas Pharma Shares Resume Trade, Now Up 40%

Financial news for ADMS dated on 2017-08-24: Adamas Pharma Shares To Resume Trade At 4:45 p.m. EDT

Financial news for ADMS dated on 2017-08-24: Adamas Pharma Resumes @4:45 PM ET

Financial news for ADMS dated on 2017-08-24: Adamas Pharma Reports FDA Approval Of GOCOVRI For Treatment Of Dyskinesia In Parkinson's Patients

Financial news for ADMS dated on 2017-08-24: UPDATE: Adamas Pharma Shares Closed Down 1%, Now Halted With News Pending Ahead Of PDUFA Decision

Financial news for ADMS dated on 2017-08-24: Adamas Pharma Shares Halted News Pending

Financial news for ADMS dated on 2017-08-24: REMINDER: Adamas Pharmaceuticals Has PDUFA Date For ADS-5102 Today

Financial news for ADMS dated on 2017-08-24: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for ADMS dated on 2017-08-08: Adamas Pharmaceuticals Reports Q2 EPS \$(0.93) vs \$(0.81) Est., Sales \$2K vs \$40K Est.

Financial news for ADMS dated on 2017-08-01: August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Financial news for ADMS dated on 2017-06-28: Adamas Pharma Names Alfred Merriweather CFO

Financial news for ADMS dated on 2017-06-15: A Peek At Adamis Ahead Of FDA Approval

Financial news for ADMS dated on 2017-06-12: Adamas Pharma Offers Results From ADS-5102 EASE LID Trial: 'Placebo-Controlled Phase 3 Trial Demonstrated that ADS-5102 Significantly Reduced Both Dyskinesia and OFF Time at Six Months in Parkinson's Disease Patients with Levodopa-induced Dyskinesia'

Financial news for ADMS dated on 2017-06-08: Adamas Pharma Reports Expansion Of ADS-5102 Open-Label Study Showing Tolerability, Durability Out To 18 Weeks

Financial news for ADMS dated on 2017-06-05: Watch These 7 Huge Call Purchases In Monday Trade

Financial news for ADMS dated on 2017-05-22: Adamas Phase 1 Results Show ADS-4101 IS Better Tolerated In Healthy Volunteers Than Equivalent Doses Of VIMPAT Immediate Release Tablets

Financial news for ADMS dated on 2017-05-11: Adamas Signs \$100M Royalty-Backed Note Agreement with HealthCare Royalty Partners

Financial news for ADMS dated on 2017-05-09: Adamas Pharmaceuticals Reports Q1 EPS \$(0.72) vs \$(0.71) Est.

Financial news for ADMS dated on 2017-04-27: Adamas Names Richard King COO

Financial news for ADMS dated on 2017-04-24: Adamas Pharma Reports Pooled Phase 3 Data for ADS-5102 Confirmed Statistical Significant Reduction in Levodopa-Induced Dyskinesia, OFF Time in People with Parkinson's

Financial news for ADMS dated on 2017-02-28: Adamas Reports Q4 EPS \$(0.68) vs \$(0.80) Est., Sales \$37K vs \$190K Est.

Financial news for ADMS dated on 2017-01-30: Adamas Pharma Sells off to Low of \$14.35 on Volume

Financial news for ADMS dated on 2017-01-08: Adamas Pharmaceuticals Says Preparing for Potential Approval and Commercialization of ADS-5102

Financial news for ADMS dated on 2017-01-06: Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia

Financial news for ADMS dated on 2016-11-15: Stifel Healthcare Conference Today

Financial news for ADMS dated on 2016-11-03: Adamas Reports Q3 Loss/Share \$0.66 vs Est Loss/Share \$0.82, Revenue \$138K vs \$220K Est

Financial news for ADMS dated on 2016-10-27: Adamas Submits New Drug Application to U.S. FDA for ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients

with Parkinson's Disease

Financial news for ADMS dated on 2016-09-22: 25 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for ADMS dated on 2016-09-22: Allergan, Adamas Report U.S. Availability of New Dosage Strengths for NAMZARIC XR

Financial news for ADMS dated on 2016-09-20: After-Hours Gainers Sept. 20, 2016: CLVS Up 10.3%, ADMS 6.1%, SPSC 5.6%, ADBE 5%, FDX 2.7%, KBH 2.2%, MSFT 1%, SRPT 1%

Financial news for ADMS dated on 2016-09-20: Adamas Reports EASE LID 3 Meets Primary And Secondary Endpoints

Financial news for ADMS dated on 2016-09-16: 25 Stocks Which Rallied Three Days

Financial news for ADMS dated on 2016-09-16: 15 Stocks With Three-Day Increasing Volume

Financial news for ADMS dated on 2016-09-15: 20 Stocks Which Rallied Three Days

Financial news for ADMS dated on 2016-09-08: Director Ericson Buys 50,919 Shares of Adamas Pharmaceuticals @\$14.79/Share -Form 4

Financial news for ADMS dated on 2016-08-31: Allergan, Adamas Announce Settlement with Amneal Related to NAMZARIC Patent Litigation; Forest & Adamas To Grant Amneal A License To Market Generic Namzaric Beginning Jan. 1, 2025

Financial news for ADMS dated on 2016-08-04: Adamas Pharmaceuticals Reports Q2 EPS \$(0.78) vs. Est. \$(0.71)

Financial news for ADMS dated on 2016-07-19: Adamas Shares Trading Up To \$16.20/Share Pre-market

Financial news for ADMS dated on 2016-07-19: Allergan and Adamas Announce New Expanded Indication for NAMZARIC Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease

Financial news for ADMS dated on 2016-06-22: Adamas Pharma Says Additional Phase 3 Clinical Program of ADS-5102 Extended-Release Capsules

Financial news for ADMS dated on 2016-06-16: Adamas Pharma Shares Up ~2% Following Earlier Upgrade to Buy from Mizuho

Financial news for ADMS dated on 2016-06-13: Adamas Pharma Reports Results from Phase 2 Proof-of-Concept Study of ADS-5102 for Treatment of Walking Impairment in MS Patients: Data Supports Further Clinical Development

Financial news for ADMS dated on 2016-05-10: Adamas Reports Q1 EPS \$(0.65) vs. Est. \$(0.76), Rev. \$175K vs. Est. \$320K

Financial news for ADMS dated on 2016-05-04: 12 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ADMS dated on 2016-04-28: 12 Stocks Moving In Thursday's Pre-Market Session

Financial news for ADMS dated on 2016-04-28: Adamas Reports PHase 3 EASE LID Meets Primary & Secondary Endpoints, Showed Statistically Significant Improvement In LID At 12 Weeks And Decrease In OFF Time vs. Placebo

Financial news for ADMS dated on 2016-04-20: Adamas Presents Positive Findings from Phase 3 EASE LID Clinical Trial of ADS-5102 for Treatment of Levodopa-induced Dyskinesia Associated with Parkinson's Disease at AACR

Financial news for ADMS dated on 2016-04-01: Benzinga's Top Initiations

Financial news for ADMS dated on 2016-04-01: JMP Securities Initiates Coverage on Adamas Pharmaceuticals at Market Outperform, Announces \$29.00 PT

Financial news for ADMS dated on 2016-02-23: Adamas Pharma Reports Q4 EPS \$(0.58) vs \$(0.94) Est., Sales \$524K vs \$200K Est.

Financial news for ADMS dated on 2016-01-19: Benzinga's Top Initiations

Financial news for ADMS dated on 2016-01-19: Cowen & Company Initiates Coverage on Adamas Pharmaceuticals at Outperform, Announces \$45.00 PT

Financial news for ADMS dated on 2016-01-19: Mizuho Securities Initiates Coverage on

Adamas Pharmaceuticals at Neutral, Announces \$26.00 PT

Financial news for ADMS dated on 2016-01-07: Here's Why There's Been A Rush Of Biotech Offerings

Financial news for ADMS dated on 2016-01-07: Adamas Prices 2.5M Share Offering @\$23.00/Share

Financial news for ADMS dated on 2016-01-06: UPDATE: Filing from Adamas Shows Forest Labs Expects to Appeal Adverse District Court Ruling at the Appropriate Time

Financial news for ADMS dated on 2016-01-06: 8-K from Adamas Pharma Shows District Court Issued Markman Ruling in Litigation from Forest Labs, Merz Pharm Filed Against Several Cos. Related to ANDAs for Generic Namenda XR

Financial news for ADMS dated on 2016-01-05: Adamas Reports Offering of 2.5M Common Shares

Financial news for ADMS dated on 2015-12-23: Mid-Afternoon Market Update: Dow Surges Over 1%; Bed Bath & Beyond Shares Slip On Lowered Q3 Outlook

Financial news for ADMS dated on 2015-12-23: Mid-Day Market Update: Crude Oil Down 4%; Adamas Pharmaceuticals Shares Jump Following Positive Phase 3 Results

Financial news for ADMS dated on 2015-12-23: Benzinga's Volume Movers

Financial news for ADMS dated on 2015-12-23: Mid-Morning Market Update: Markets Open Higher; Nike Profit Tops Expectations

Financial news for ADMS dated on 2015-12-23: Adamas Pharmaceuticals Surges 30% Following Positive Phase 3 Results

Financial news for ADMS dated on 2015-12-23: Benzinga's Top #PreMarket Gainers

Financial news for ADMS dated on 2015-12-23: Adamas Announces Positive Top Line Phase 3 Results for ADS-5102

Financial news for ADMS dated on 2015-12-23: Adamas Announces Positive Top-Line Phase 3 Results of ADS-5102 for Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease

Financial news for ADMS dated on 2015-11-12: Adamas Reports Q3 EPS (\$0.81) vs. Est. (\$0.84), Rev. \$768K vs. Est. \$90K

Financial news for ADMS dated on 2015-10-12: UPDATE: Adamas Senior VP, Product Development Says With Improved ADS-5102 Profile, 'we can potentially administer higher therapeutic doses than is common with immediate release amantadine'

Financial news for ADMS dated on 2015-10-12: Adamas Presents Nonclinical Findings Supporting the Potential Use of ADS-5102 for the Treatment of Multiple Sclerosis Gait

Financial news for ADMS dated on 2015-09-22: Why Aegis Capital Loves Adamas...And How To Bet On Parkinson's Treatment

Financial news for ADMS dated on 2015-09-22: Aegis Capital Initiates Coverage on Adamas Pharmaceuticals at Buy, Announces \$29.00 PT

Financial news for ADMS dated on 2015-08-11: Adamas Pharma Reports Q2 Loss \$0.78 Vs Est Loss \$0.72, Sales \$398K vs Est \$30.00K

Financial news for ADMS dated on 2015-07-09: Adamas Finishes Recruitment of Its Phase 3 EASE LID Study Evaluating ADS-5102 for the Treatment of Levodopa-induced Dyskinesia Associated With Parkinson's Disease

Financial news for ADMS dated on 2015-07-07: Adamas Pharmaceuticals Issued U.S. Patent Relating to ADS-5102 Program

Financial news for ADMS dated on 2015-06-11: Adamas Starts Phase 2 Clinical Trial Assessing ADS-5102 for Treating Multiple Sclerosis Symptoms in Patients With Walking Impairment

Financial news for ADMS dated on 2015-05-27: 2 Small Cap Pharma Stocks Credit Suisse Loves

Financial news for ADMS dated on 2015-05-19: Adamas Pharmaceuticals Files for Up to \$150M Stock Shelf

Financial news for ADMS dated on 2015-05-13: Adamas Pharma Reports Q1 Loss of \$0.69/Share vs Loss of \$0.74/Share Est.

Financial news for ADMS dated on 2015-04-10: Adamas Pharma Announces Receiving of Orphan Drug Designation for ADS-5102

Financial news for ADMS dated on 2015-03-31: Adamas Pharma Issues Patent

Financial news for ADMS dated on 2015-03-03: Adamas Reports Q4 EPS \$0.53 vs. \$(0.24), Rev. \$55M vs. \$10M

Financial news for ADMS dated on 2015-01-11: Adamas Pharmaceuticals Recaps 2014 Achievements, Previews Upcoming Business Drivers

Financial news for ADMS dated on 2015-01-08: Adamas Pharmaceuticals Receives \$30M Payment From Actavis

Financial news for ADMS dated on 2014-12-26: Mid-Day Market Update: Crude Oil Slides Over 1%; American Apparel Shares Jump

Financial news for ADMS dated on 2014-12-26: Stocks To Watch For December 26, 2014

Financial news for ADMS dated on 2014-12-24: #Premarket Prep Technical Update - Adamas Pharmaceuticals Sharply Higher

Financial news for ADMS dated on 2014-12-24: Benzinga's Volume Movers

Financial news for ADMS dated on 2014-12-24: Morning Market Movers

Financial news for ADMS dated on 2014-12-24: FDA Approves Adamas Pharmaceuticals' Alzheimer's Drug, Shares Soar

Financial news for ADMS dated on 2014-12-24: Adamas Pharmaceuticals Shares Rise 20% Premarket on FDA Approval of Alzheimer's Treatment

Financial news for ADMS dated on 2014-12-24: Actavis, Adamas Report FDA Approval of Namzaric for Treatment of Moderate to Severe Alzheimer's

Financial news for ADMS dated on 2014-12-02: Adamas Pharmaceuticals Issued Six Additional U.S. Patents

Financial news for ADMS dated on 2014-11-04: Adamas Pharmaceuticals Reports Q3 EPS of \$(0.57) vs \$(0.44) Est

Financial news for ADMS dated on 2014-10-28: Adamas Pharmaceuticals Expands Its Phase 3 Program With ADS-5102

Financial news for ADMS dated on 2014-09-23: 5 Healthcare Stocks With The Highest Operating Margin

Financial news for ADMS dated on 2014-08-13: Adamas Pharma Names Jeff Knapp as COO, Bill Dawson Replacing Tony Rimac as CFO

Financial news for ADMS dated on 2014-08-07: Adams Pharma EPS \$0.88, Rev \$25.2M

Financial news for ADMS dated on 2014-08-05: USPTO Issues Patent to Adamas Pharmaceuticals

Financial news for ADMS dated on 2014-06-23: Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

Financial news for ADMS dated on 2014-06-10: Adams Pharma Announces Rater Training Data on ADS-5102, Says Phase 2/3 Eased Study Met Primary Endpoint

Financial news for ADMS dated on 2014-06-09: Adamas Issued Patent

Financial news for ADMS dated on 2014-06-09: Adamas Initiates Phase 3 Trial For ADS-5102

Financial news for ADMS dated on 2014-05-21: Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Financial news for ADMS dated on 2014-05-20: Adamas Pharmaceuticals Recieves \$25M Milestone Payment From Forest Labs

Financial news for ADMS dated on 2014-05-13: Adamas Pharmaceuticals Reports Q1 EPS of \$(0.67)

Financial news for ADMS dated on 2014-05-05: Benzinga's Top Initiations

Financial news for ADMS dated on 2014-05-05: Needham Initiates Coverage on Adamas

Pharmaceuticals at Buy, Announces \$33.00 PT

Financial news for ADMS dated on 2014-05-05: William Blair Initiates Coverage on Adamas Pharmaceuticals at Outperform, Announces \$35.00 PT

Financial news for ADMS dated on 2014-05-05: Piper Jaffray Initiates Coverage on Adamas Pharmaceuticals at Overweight, Announces \$32.00 PT

Financial news for ADMS dated on 2014-04-16: Adamas Pharmaceuticals Shareholder MDV VII LP Buys 300,000 Shares at \$16.00/Share -Form 4

Financial news for ADMS dated on 2014-04-15: Adamas Pharmaceuticals Announces Closing of Initial Public Offering, Estimates Net Proceeds of \$41.5M

Financial news for ADMS dated on 2014-04-15: Adamas Pharmaceuticals Announces Closing of Initial Public Offering, Estimates Net Proceeds of \$41.5M

Financial news for ADMS dated on 2014-04-12: IPO Review For The Week Of April 7: IPOs Outperform S&P 500...Again

Financial news for ADMS dated on 2014-04-11: IPO Wrapup for the Week of April 7th, 2014

Financial news for ADMS dated on 2014-04-11: IPO Outlook for Friday, April 11: City Office, Paycom Software, Farmland Partners & More

Financial news for ADMS dated on 2014-04-10: Adamas Pharma Shares Open at \$16.85/Share, Priced at \$16

Financial news for ADMS dated on 2014-04-10: IPO Investor Outlook For Thursday, April 10

Financial news for ADMS dated on 2014-04-07: IPO Lookout: IPOs For The Week Of April 7, 2014